Mavacamten in oHCM: Navigating the REMS Program for Safe, Optimal Outcomes

Author(s):

Anjali Tiku Owens, MD, examines mavacamten, the pioneering cardio myosin inhibitor (CMI) approved for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), which is exclusively accessible through the restricted Risk Evaluation and Mitigation Strategy (REMS) program; the KOL delves into the objectives of this program and how it strives to enhance medication safety and optimize patient outcomes.

EP: 1.Novel Cardiac Myosin Inhibitors Targeting Obstructive Hypertrophic Cardiomyopathy's Root Cause

EP: 2.Lessons from EXPLORER-HCM: Unveiling CMIs' Potential in oHCM Treatment

EP: 3.Aligning With 2023 ESC Guidelines in oHCM Treatment

Now Viewing

EP: 4.Mavacamten in oHCM: Navigating the REMS Program for Safe, Optimal Outcomes

EP: 5.Real-World Insights: Navigating Cardiac Myosin inhibitors in Practice

Mavacamten is the first approved CMI for oHCM and is only available through the restricted Risk Evaluation and Mitigation Strategy (REMS) program. What is the purpose of this program, and how does it aim to improve medication safety and patient outcomes?
How does your institution/clinic handle the execution of the REMS program for mavacamen, how do you get certified, what are the institutional protocols?

What is needed from the patient? REMS program patient